Zobrazeno 1 - 10 of 39 pro vyhledávání: '"Milena Kurtinecz"'
2
Akademický článek
Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme
Autor: Rafael Perera, Richard Stevens, Jeffrey K Aronson, Amitava Banerjee, Julie Evans, Benjamin G Feakins, Susannah Fleming, Paul Glasziou, Carl Heneghan, FD Richard Hobbs, Louise Jones, Milena Kurtinecz, Daniel S Lasserson, Louise Locock, Julie McLellan, Borislava Mihaylova, Christopher A O’Callaghan, Jason L Oke, Nicola Pidduck, Annette Plüddemann, Nia Roberts, Iryna Schlackow, Brian Shine, Claire L Simons, Clare J Taylor, Kathryn S Taylor, Jan Y Verbakel, Clare Bankhead
Publikováno v: Programme Grants for Applied Research, Vol 9, Iss 10 (2021)
Background: Long-term monitoring is important in chronic condition management. Despite considerable costs of monitoring, there is no or poor evidence on how, what and when to monitor. The aim of this study was to improve understanding, methods, evide
Externí odkaz: https://doaj.org/article/41b3c5a60e2444a791bd8cfe2995ced1
Zobrazit plný text záznamu
4
Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI
Autor: Matthieu Carton, Johanna Peña Del Castillo, Jean-Baptiste Colin, Milena Kurtinecz, Marion Feuilly, Gaëlle Pierron, Pierre Arvis, Soumeya Khadidja Khadir, Monika Sparber-Sauer, Daniel Orbach
Publikováno v: Future Oncology.
The EPI VITRAKVI study is a retrospective study designed to place the results of the single-arm Phase I/II larotrectinib SCOUT trial into context by comparison with external historical controls. Its primary objective is to compare the time to medical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b43c08202b0c62ea3c3e3dbe67649a47
https://doi.org/10.2217/fon-2023-0114
Zobrazit plný text záznamu
5
Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study
Autor: Kambiz, Rahbar, Markus, Essler, Kim M, Pabst, Matthias, Eiber, Christian Peter, la Fougère, Vikas, Prasad, Philipp, Rassek, Ergela, Hasa, Helmut, Dittmann, Ralph A, Bundschuh, Wolfgang Peter, Fendler, Milena, Kurtinecz, Anja, Schmall, Frank, Verholen, Alton O, Sartor
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer.This pre-planned, interim, retrospective analysis investigated safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fe21c2514cebe95a5ef68841a4a26091
https://pubmed.ncbi.nlm.nih.gov/36302656
Zobrazit plný text záznamu
7
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
Autor: Michelle Petri, Helain Landy, Megan E B Clowse, Kim Gemzoe, Munther Khamashta, Milena Kurtinecz, Roger A Levy, Andrew Liu, Rebecca Marino, Paige Meizlik, Jeanne M Pimenta, Kelsey Sumner, Hugh Tilson, Mary Beth Connolly, Keele Wurst, Julia Harris, Holly Quasny, Patricia Juliao, David A Roth
Publikováno v: Annals of the rheumatic diseases.
ObjectiveDescribe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab.MethodsData collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89074e9b85c37b8e47d72849d2bbeab0
https://pubmed.ncbi.nlm.nih.gov/36198440
Zobrazit plný text záznamu
8
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Autor: Zahi Touma, Johannes von Kempis, Josefina Cortés-Hernández, Kerry Gairy, Milena Kurtinecz, Christopher E Collins, Andreas Schwarting, Mercedes A. Garcia
Publikováno v: Rheumatology and Therapy
Introduction The real-world effectiveness of belimumab for systemic lupus erythematosus (SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc analysis (GSK study 206351) was to pool individual patient OBSErve data to f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227b0065074d075dd33442e14fdf5708
http://europepmc.org/articles/PMC7695800
Zobrazit plný text záznamu
10
Time interval between radium-223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study
Autor: Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Kim M. Pabst, Wolfgang Peter Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Milena Kurtinecz, Anja Schmall, Frank Verholen, A. Oliver Sartor
Publikováno v: Journal of Clinical Oncology. 41:73-73
73 Background: 223Ra and 177Lu-PSMA-617 both prolong overall survival (OS) in different mCRPC settings. The observational, retrospective study, RALU, investigated safety and clinical outcomes of sequential 223Ra/177Lu-PSMA therapy in patients (pts) w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f456e5a2ec2107f20fbb831185b71840
https://doi.org/10.1200/jco.2023.41.6_suppl.73
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje